10x Genomics, Inc. - TXG STOCK NEWS

10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management team will engage in a fireside chat on Wednesday, September 4, at 10:45 a.m. Eastern Time.

Interested parties can access a live webcast of the fireside chat through the "Investors" section of 10x Genomics' website at https://investors.10xgenomics.com/. The webcast will remain archived and available for replay for at least 45 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.

10x Genomics (NASDAQ: TXG) has announced significant changes to its executive team on August 8, 2024. Mennah Moustafa has been appointed as Chief Commercial Officer effective August 1, 2024. She will oversee commercial strategy, sales, support, and marketing. Justin McAnear, the current CFO, will resign on August 30 to join a private company. Adam Taich will take over as CFO on August 12, 2024, leading the company's financial team and strategy.

CEO Serge Saxonov highlighted the company's ongoing evolution aimed at driving growth and innovation. The leadership changes are part of the broader strategy to strengthen commercial functions and financial management, aided by the recent Board additions of Alan Mateo and Sarah Teichmann.

Moustafa, having proven herself as interim CCO, brings over 20 years of experience in biotechnology and life sciences. Taich, with a strong background in finance and life sciences, joins from Standard BioTools. The company aims for continued growth and leadership in single cell and spatial biology.

10x Genomics (Nasdaq: TXG) reported Q2 2024 financial results with revenue of $153.1 million, a 4% increase year-over-year. The company began shipping Xenium Prime 5K, featuring enhanced chemistry and integrated multimodal cell segmentation. Gross margin remained flat at 68%, while operating expenses decreased by 10% to $146.0 million. The operating loss narrowed to $41.7 million from $63.4 million in the prior year period. Net loss improved to $37.9 million compared to $62.4 million last year. Cash and equivalents stood at $380.1 million as of June 30, 2024. 10x Genomics updated its full-year 2024 revenue guidance to $640-$660 million, representing 3-7% growth over 2023.

10x Genomics (Nasdaq: TXG) is supporting the TenK10K project, a large-scale study led by the Garvan Institute of Medical Research. The project aims to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases, and cancer. The Garvan Institute has selected 10x Genomics' Chromium GEM-X products for single cell data generation, which offers increased sensitivity, throughput, data quality, and sample recovery.

The TenK10K project builds on the success of the Garvan Institute's OneK1K study and aims to develop commercial tests for various autoimmune diseases, early trials of RNA therapies, and potential treatments for cancers and long COVID. This collaboration showcases the potential of single cell analysis at a massive scale to impact disease understanding, diagnosis, treatment, and cure.

10x Genomics (Nasdaq: TXG) announced that it will release its Q2 2024 financial results on August 8, 2024, after market close. The company will hold a conference call and live webcast for investors and analysts at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. The financial results will be accessible on the company's website before the call. The live webcast will be available on the 'Investors' section of the website and will be archived for replay for at least 45 days.

On June 27, 2024, 10x Genomics (Nasdaq: TXG) announced that its Xenium In Situ platform was instrumental in a groundbreaking study published in the Journal of Dental Research. Led by NIH researchers and computational experts from the University of Connecticut, the study provided new insights into the cellular mechanisms of secondary palate formation. This research utilized the Chromium Single Cell products and Xenium In Situ to explore gene expression regulation in developing palates, revealing the role of Pax9 in Wnt signaling. The study shows that disrupting Wnt signals in Pax9-deficient mice affects bone formation, with potential implications for innovative cleft palate treatments.

The researchers created a custom gene expression panel to profile 350 genes at single-cell spatial resolution, revealing notable differences between wild-type and Pax9-deficient mice. The results suggest that targeting these pathways could lead to new diagnostic and therapeutic strategies for cleft palate anomalies, affecting about 1 in 700 live births globally.

10x Genomics (Nasdaq: TXG) has commenced commercial shipments of its new Xenium Prime 5K Pan-Tissue and Pathways panel. This advanced panel features a 5,000-plex gene capability, significantly enhancing plex capacity while maintaining top-tier per-gene sensitivity, specificity, and spatial fidelity. It also integrates multimodal cell segmentation, offering industry-leading speed and throughput. Optimized for comprehensive profiling of cell types, states, and signaling pathways across various tissues and diseases, the Xenium Prime 5K assay allows for rapid analysis of up to 472 mm² of tissue in under six days. Customizable with up to 100 additional genes, the assay is compatible with fresh frozen and FFPE samples, providing an easy, tissue-agnostic workflow. A webinar to introduce the product is scheduled for June 25, 2024.

10x Genomics announced the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel, significantly enhancing single-cell and spatial biology research. The new panel boasts a tenfold increase in plex capacity, improved per-gene sensitivity, specificity, and spatial fidelity. Key features include rapid turnaround time, customizable options, and the capability to analyze extensive tissue areas efficiently. Optimized for human and mouse species, the panel is now available for preorder, with shipments expected next month. This innovation aims to advance the exploration of molecular pathways, biomarkers, and cell interactions in various diseases.

10x Genomics, a leader in single cell and spatial biology, will be presenting at the BofA Securities 2024 Healthcare Conference. The company's management team will participate in a fireside chat on May 14 at 4:20 p.m. Pacific Time. Interested parties can access a live webcast of the event on the company's website.